The Regulators of Complement Activation cluster at chromosome 1q32 contains the genes encoding the complement regulator factor H and five factor H related proteins. This is an area of the genome that arose from several large genomic duplications and these low copy repeats can cause genome instability in this region.
The genes encoding complement factor H (CFH) and the factor H related proteins (CFHRs1-5) reside in a 360-kb region in the Regulators of Complement Activation (RCA) cluster on chromosome 1q32 (figure 1a) 1 . This is an area of the genome that arose from several large genomic duplications 2, 3 and these low copy repeats can cause genome instability in this region.
Mutations in CFH are the most common genetic predisposition to the thrombotic microangiopathy, atypical haemolytic uraemic syndrome (aHUS) 4 . The majority of mutations in CFH occur at the C-terminal end responsible for host polyanion binding [5] [6] [7] .
Several of these CFH mutations (e.g.S1191L; V1197A) have been demonstrated to be gene conversion events between CFH and CFHR1 .
Recently a "reverse" CFHR1/CFH hybrid gene arising through NAHR has been described in aHUS. This encodes a FHR1 where the C terminal CCPs are replaced by the C terminal CCPs of FH 12, 13 . Unlike previously reported hybrid proteins, this does not impair FH cell surface binding, but instead acts as a competitive inhibitor of FH 13 .
In this study we report a novel CFH/CFHR3 hybrid gene arising through MMEJ which impairs cell surface complement regulation.
(0.35-0.59g/L). He commenced plasma exchange and required 3 sessions of haemofiltration. A renal biopsy confirmed a thrombotic microangiopathy (figure 2).
Creatinine returned to a baseline of ~100 μmol/L. He was treated with weekly plasma exchange for three and a half years prior to starting Eculizumab on which he has been region of microhomology (figure 1d). The deletion was not detected in either parent suggesting that this was a de novo event.
We hypothesised that the loss of CFH exons 21, 22, 23 and the 3'UTR of CFH would lead to aberrant splicing. In silico analysis showed that the next acceptor splice site, following the CFH exon 20 donor site, was 5' of CFHR3 exon 2, thus potentially producing a transcript for a hybrid CFH/CFHR3 gene (supplementary figure 2).
Messenger RNA for this putative hybrid CFH/CFHR3 gene was confirmed by amplifying patient and control cDNA with CFH and CFHR3 specific primers. This demonstrated a product in the patient and not in healthy controls (figure 1e).
To confirm that this hybrid transcript led to the synthesis and secretion of a hybrid protein, western blotting was performed using a series of epitope-defined anti-FH monoclonal antibodies ( figure 3a ). An initial blot probed with OX24, a FH CCP5-specific antibody, demonstrated, in addition to FH, two additional bands only in the patient (figure 3b). The species at~160kDa was consistent with the predicted intact hybrid FH/FHR3. A species at~120kDa, was hypothesised to be a degradation product. No abnormal bands were detected in either parent (supplementary figure 3a) .
A FH C-terminal specific antibody (L20/3) did not reveal additional aberrant bands, indicating that these protein species lacked FH CCP20 (Fig 3c) . Genotyping showed the patient to be heterozygous for the Y402H polymorphism in FH. This allowed the use of monoclonal antibodies specific for histidine or tyrosine in CCP7 of FH
14
. The CFH/CFHR3 hybrid gene in aHUS 5 normal allele's product reacted to the histidine specific mAb (MBI7) and gave a single band of~150kDa consistent with FH. The hybrid allele reacted to the tyrosine specific mAb (MBI6), demonstrating a doublet at~160Kda (figure 3d). FHR3 is known to be alternately glycosylated 15-17 and we hypothesise that the doublet is due to an alternately gylcosylated hybrid protein. Additionally it can be seen that the presumed degradation product at 120kDa, is only seen using the tyrosine specific mAb, consistent with this only arising from the hybrid protein.
To confirm these findings, FH species were purified from serum using affinity chromatography with an OX24 mAb. These were separated by a 6% SDS PAGE prior to trypsin digestion. Mass spectrometry was then carried out on these three purified bands (figure 4a). Peptide species identified from the~160kDa band confirmed that this was a hybrid FH/FHR3 protein. Protein fragments from the 150kDa band were consistent with FH. Fragments from CCPs 5, 6, 8, 9 and 14 of FH were seen in the band at~120kDa. Coverage at CCP7 was insufficient to determine whether there was a tyrosine or histidine at position 402. The western blot analysis and mass spectrometry data together show that breakdown products from only the hybrid protein are seen in serum.
To examine the functional significance, the FH/FHR3 hybrid protein was purified from serum using affinity chromatography with an MBI6 mAb followed by gel filtration (supplementary figure 3b) . The FH/FHR3 hybrid protein displayed both impaired cell surface decay acceleration (figure 4b) and cofactor activity (figure 4c).
Thus, in this study we demonstrate a deletion in the RCA cluster resulting in a ) are required for disease to manifest 4, 22 . In this case, STEC served to unmask the genetic predisposition to disease as in 2 previously reported cases of STEC triggered aHUS 23 .
In summary we describe a deletion in the RCA cluster arising through MMEJ which results in a novel CFH/CFHR3 hybrid gene. That, this arose as a de novo event suggests that this is a dynamic area of the genome where we should expect further genomic disorders.
Concise Methods
The study was approved by Newcastle and North Tyneside 1 Research Ethics Committee, and informed consent was obtained in accordance with the Declaration of Helsinki.
Complement Assays
C3 and C4 levels were measured by rate nephelometry (Beckman Coulter Array 360). FH levels were measured by radial immunodiffusion (Binding Site). Screening for FH autoantibodies was undertaken using ELISA as described previously 24 . 
Genetic Analysis and Multiplex ligation-dependent probe amplification

Genomic breakpoint analysis
To identify the breakpoint of the deletion that resulted in the CFH/CFHR3 hybrid gene, genomic DNA was amplified using a forward primer specific for CFH in exon 20
and a reverse primer in the CFH 3' region (figure 1c). The sequence of the forward primer was GTAACTGTTATCAGTTGATTTGC, and the reverse was ACGGATTGCATGTATAAGTG. The product was then sequenced using direct fluorescent sequencing.
Confirmation of CFH/CFHR3
RNA product mRNA was extracted from peripheral blood lymphocytes of the patient and cDNA was prepared. This was amplified using a forward primer in CFH exon 20
(TGGATGGAGCCAGTAATGTAACATGCAT) and a reverse primer in CFHR3 exon 2 (GAAATAGACCTCCATGTTTAATGTCTG) (figure 1c). The PCR product was detected in an ethidium bromide-stained 1.5% agarose gel
Western blotting
Detection of abnormal protein products in serum arising as a consequence of the deletion was undertaken by Western blotting. Sera was diluted 1/100 and under non- (secondary Ab) (supplementary methods). Following washes in 1xTBST, blots were developed using Pierce ECL Western blotting substrate (Thermo Scientific).
Purification of factor H species FH species (WT FH from normal allele, FH/FHR3 hybrid and FH/FHR3
breakdown product all with CCP5 of FH) were purified from serum with affinity chromatography using immobilised monoclonal antibody to FH (OX24), on a 1 mL HiTrap NHS HP column (GEHealthcare). Following washing with PBS, the bound proteins were then eluted using 0.1M glycine pH2.7. The eluted material was pooled and concentrated for analysis by mass spectrometry.
The FH/FHR3 hybrid protein was purified from patient serum with affinity chromatography using immobilised monoclonal antibody to FH CCP7 402Y (MBI6) 31 , on a 1 mL HiTrap NHS HP column (GEHealthcare). Following washing with PBS, the bound proteins were eluted using PBS/diethylamine (50mM). Subsequently the FH/FHR3 protein was purified from its degradation product and FHL1 using a Superdex 200 size exclusion column. We also purified WT FH protein from a healthy control. FH or FH/FHR3 hybrid protein purified using the MBI6 column was used for cofactor and decay acceleration assays.
Mass Spectrometry
A 6% SDS PAGE was run and the 3 bands identified by coomassie staining were excised from the gel as indicated in figure 4a. Trypsin digest and mass spectrometry were then undertaken (supplementary methods).
Cell surface decay acceleration assays
Decay acceleration on sheep erythrocytes was performed as previously described 32 and in supplementary methods. Briefly, FH/FHR3 hybrid from the patient and FH from control were purified by immuno-affinity chromatography as above and gel filtered into PBS. Alternative pathway convertase (C3bBb) was formed on sheep erythrocytes. 
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Mass Spectrometry
The eluted material was pooled and concentrated to 30uL. This was then run on a 6% SDS PAGE, 3 bands identified by coomassie staining, were excised from the gel as indicated in figure 4a. Proteins were reduced with 10 mM DTT (Sigma) in 100 mM NH 4 HCO 3 , alkylated with 50 mM iodoacetamide (Sigma) in 100 mM NH 4 HCO 3 and digested in gel with 230ng modified trypsin (Promega) in 50 mM NH 4 HCO 3 , 1 mM CaCl 2 . Peptides were extracted from the gel pieces and the digests were analysed by LCMSMS using a Dionex U3000 nano-HPLC system (Thermo) coupled to an Orbitrap LTQ XL(ETD) (Thermo) mass spectrometer. Peptides were separated on a 25 cm x 75 µm PepMap column (Thermo) using a 37 min water acetonitrile gradient (0.05% formic acid). Precursor ions were detected in positive mode at 350-1600 m/z with a resolution of 60,000 (at 400 m/z) and a fill target of 500,000 ions and a lockmass was set to 445.120023 m/z. The five most intense ions of each MS scan (with a target value of 10,000 ions) were isolated, fragmented and measured in the linear ion trap. Peaklists in the Mascot generic format (*.mgf) were generated using msconvert (proteowizard.sourceforge.net (Kessner et al., 2008) ) and the ensembl human genome (GrCh37.66) was searched using X!Tandem and the gom interface 
